Akari Therapeutics (NASDAQ:AKTX) Posts Quarterly Earnings Results, Misses Expectations By $686.67 EPS

Akari Therapeutics (NASDAQ:AKTX) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($688.00) EPS for the quarter, missing the consensus estimate of ($1.33) by ($686.67), reports.

Akari Therapeutics Stock Up 255.4%

AKTX traded up $13.13 on Friday, hitting $18.27. The company had a trading volume of 33,346,866 shares, compared to its average volume of 424,160. The company’s fifty day moving average price is $5.37 and its 200 day moving average price is $10.53. Akari Therapeutics has a 1-year low of $3.02 and a 1-year high of $56.80.

Key Stories Impacting Akari Therapeutics

Here are the key news stories impacting Akari Therapeutics this week:

• Positive Sentiment: Akari reported breakthrough preclinical data showing AKTX-101 worked synergistically with KRAS inhibition in pancreatic cancer models, boosting investor optimism about its lead ADC program. Article Title
• Positive Sentiment: Market commentary highlighted the stock’s surge after the cancer-data release, with some traders pointing to possible upside if the platform continues to show promise. Article Title
• Neutral Sentiment: Akari announced a $5.5 million private placement offering to fund development of AKTX-101, providing near-term cash but also signaling dilution risk. Article Title
• Neutral Sentiment: The company also announced an ADS ratio change and reverse split, a corporate action that can alter the share structure and often contributes to trading volatility. Article Title
• Negative Sentiment: Akari’s latest quarterly results missed expectations by a wide margin, underscoring that the company remains highly speculative and financially challenged. Article Title
• Negative Sentiment: Trading in AKTX was halted multiple times for LULD pauses, reflecting extreme intraday volatility as investors reacted to the news flow. Article Title

Analyst Upgrades and Downgrades

AKTX has been the subject of several recent research reports. Maxim Group cut Akari Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. HC Wainwright boosted their price target on Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Akari Therapeutics has an average rating of “Hold” and a consensus price target of $89.00.

Institutional Investors Weigh In On Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC bought a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.